CAH's Specialty Momentum Accelerates, but Valuation Leaves Little Room for Error

What happened

Cardinal Health's Pharmaceutical & Specialty Solutions segment delivered another standout quarter in fiscal Q3 2026, with revenues climbing 19% to roughly $61 billion and segment profit surging 29%, confirming the division's role as the primary growth engine. This performance aligns with the company's multiple guidance raises and underscores the successful pivot toward higher-margin specialty distribution and MSO platforms. However, the stock now trades at approximately 22x the raised FY26 non-GAAP EPS floor of $10 and 17.8x EV/EBITDA, embedding expectations for sustained double-digit growth and flawless integration of recent acquisitions. The DeepValue report flags that earnings quality is increasingly dependent on non-GAAP adjustments, leverage is rising, and customer concentration—with CVS representing ~30% of revenue—exposes the company to asymmetric downside from any contract disruption or policy headwind. Thus, while the latest quarter validates the specialty thesis, the current valuation offers limited margin of safety and leaves little room for error.

Implication

Over the next 12-18 months, any hiccup in guidance, MSO integration, or policy-driven margin compression could trigger multiple compression. Investors should consider trimming positions on strength and waiting for a pullback or clearer FY27 visibility before adding.

Thesis delta

The Q3 numbers confirm that Cardinal's specialty pivot is delivering, but this is now widely recognized and largely priced in. The risk/reward has not improved from the previous assessment—if anything, the bar for future upside has risen. The thesis remains that from today's valuation, downside risks from leverage, CVS concentration, and policy uncertainty outweigh the potential for further multiple expansion.